

Special Issue

Cancer Chemotherapy Resistance

Message from the Guest Editor

Chemotherapy remains one of the most successful therapeutic approaches to cancer treatment. It uses anti-cancer drugs with different modes of action to destroy cancer cells. The major problems of chemotherapy are the development of cancer drug resistance and side effects. Tumours may be intrinsically drug-resistant or develop resistance to chemotherapy during this treatment, and acquired resistance is especially a particular problem. Tumours become resistant to used drugs but may also become cross-resistant to other drugs with different mechanisms of action. Even though different anti-cancer drugs have been in clinical use for more than forty years and represent one of the major topics of investigation in cancer research, the problem of drug resistance remains unsolved. This Special Issue will focus on the characterisation of novel molecular mechanisms, the signalling pathways involved in regulating tumour response to chemotherapy, and novel targets which can combat drug resistance. Our main aim is to predict responses to chemotherapy and modulate these responses with targeted therapies with the goal of selecting the best treatment for individual patients.

Guest Editor

Dr. Anamaria Brozovic

Ruđer Bošković Institute, Division of Molecular Biology, Bijenička cesta 54, 10000 Zagreb, Croatia

Deadline for manuscript submissions

closed (1 July 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/124049

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)